Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy.
Meric-Bernstam
Funda
F
Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA. fmeric@mdanderson.org
Esteva
Francisco J
FJ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005819:Genetic Markers; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000494:pharmacology; D018579:Patient Selection; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism; D020123:Sirolimus / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D005819:Genetic Markers; D047908:Intracellular Signaling Peptides and Proteins; C015482:protein kinase modulator; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus